Othman AA - Search Results

1

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. Feagan BG, et al. Among authors: othman aa. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):671-680. doi: 10.1016/S2468-1253(18)30233-4. Epub 2018 Jul 25. Lancet Gastroenterol Hepatol. 2018. PMID: 30056030 Free article. Clinical Trial.

2

Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.

Minocha M, Tran JQ, Sheridan JP, Othman AA. Minocha M, et al. Among authors: othman aa. Clin Pharmacokinet. 2016 Jan;55(1):121-30. doi: 10.1007/s40262-015-0305-z. Clin Pharmacokinet. 2016. PMID: 26242380 Clinical Trial.

3

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.

Haig G, Wang D, Othman AA, Zhao J. Haig G, et al. Among authors: othman aa. Neuropsychopharmacology. 2016 Nov;41(12):2893-2902. doi: 10.1038/npp.2016.101. Epub 2016 Jun 20. Neuropsychopharmacology. 2016. PMID: 27319970 Free PMC article. Clinical Trial.

4

Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.

Haig GM, Wang D, Zhao J, Othman AA, Bain EE. Haig GM, et al. Among authors: othman aa. J Clin Psychiatry. 2018 May/Jun;79(3):16m11162. doi: 10.4088/JCP.16m11162. J Clin Psychiatry. 2018. PMID: 28922590 Clinical Trial.

5

Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.

Minocha M, Zeng J, Medema JK, Othman AA. Minocha M, et al. Among authors: othman aa. Clin Pharmacokinet. 2018 Sep;57(9):1185-1198. doi: 10.1007/s40262-017-0625-2. Clin Pharmacokinet. 2018. PMID: 29333561 Clinical Trial.

6

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS. Burmester GR, et al. Among authors: othman aa. Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18. Lancet. 2018. PMID: 29908669 Clinical Trial.

7

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.

Suleiman AA, Khatri A, Minocha M, Othman AA. Suleiman AA, et al. Among authors: othman aa. Clin Pharmacokinet. 2019 Mar;58(3):375-387. doi: 10.1007/s40262-018-0704-z. Clin Pharmacokinet. 2019. PMID: 30123942 Free PMC article. Clinical Trial.

8

Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis.

Othman AA, Khatri A, Loebbert R, Peloso PM. Othman AA, et al. Clin Pharmacol Drug Dev. 2019 May;8(4):492-502. doi: 10.1002/cpdd.611. Epub 2018 Aug 29. Clin Pharmacol Drug Dev. 2019. PMID: 30156758 Clinical Trial.

9

Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.

Khatri A, Cheng L, Camez A, Ignatenko S, Pang Y, Othman AA. Khatri A, et al. Among authors: othman aa. Clin Pharmacokinet. 2019 Jun;58(6):805-814. doi: 10.1007/s40262-018-0730-x. Clin Pharmacokinet. 2019. PMID: 30574672 Clinical Trial.

10

Models of Variability and Circadian Rhythm in Heart Rate, Blood Pressure, and QT Interval for Healthy Subjects Who Received Placebo in Phase I Trials.

Minocha M, Li H, Chiu YL, Carter D, Othman AA. Minocha M, et al. Among authors: othman aa. Clin Transl Sci. 2019 Sep;12(5):470-480. doi: 10.1111/cts.12640. Epub 2019 Jun 4. Clin Transl Sci. 2019. PMID: 31021448 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

233 results

Search Page

Filters